Flashback Technologies

Deploy FDA-cleared hemorrhage detection. Department ($2,400/bed/yr), Hospital ($1,800/bed/yr) with EMR integration, or Enterprise custom plans. 90-day pilot available.

The page demonstrates how CipherOx’s system monitors compensatory reserve depletion up to 30 minutes before vital sign changes using clinical simulations.

Detect hemorrhage 30 minutes before vital signs change. CipherOx CRI-M1 uses Compensatory Reserve Index to identify blood loss with 94% sensitivity. FDA 510(k) cleared.

Flashback Technologies Inc appoints **Marcus Barkham** as its new CEO and plans a company rebrand. The firm specializes in AI-driven digital healthcare solutions, leveraging machine learning to develop its technology offerings. This leadership change follows the company’s focus on scaling its healthcare innovations.

Jul 2022PR NewswireNews article

Flashback Technologies receives U.S. FDA clearance for its **CipherOx CRI M1 monitor**, a device using the **Compensatory Reserve Index (CRI)** to detect and track acute blood loss noninvasively. The technology provides rapid, real-time hemodynamic status readings without traditional invasive methods. The clearance enables broader clinical use in patient monitoring.

Jul 2018BioSpaceNews article

The U.S. Army’s **Tiny Life-Saving Device** obtains FDA clearance for use. The compact medical tool addresses critical battlefield and emergency care needs, though specific applications or design details remain undisclosed in the announcement.

Jan 2017www.army.milNews article

Flashback Technologies receives U.S. FDA De Novo clearance for its first medical device, integrating the **Compensatory Reserve Index (CRI)** algorithm. The CRI serves as an **adjunctive cardiovascular status indicator**, aiding in monitoring patients at risk for **hemodynamic instability**. This clearance marks a milestone for non-invasive patient monitoring solutions.

Jan 2017BioSpaceNews article